Michael Tran, MD
Ophthalmology · Fountain Valley, CANPI 1801888110
Payments from drug & device makers
Across 231 payments — averaging $377.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch Health US, LLC$69K
- Kala Pharmaceuticals, Inc.$9K
- Alcon$4K
- Vertical Pharmaceuticals, LLC$2K
- Amgen$753
- Johnson & Johnson Surgical Vision, Inc.$512
- plus $3K from 20 others
Across 7 payments — averaging $3456.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kala Pharmaceuticals, Inc.$24K
What the payments were for
- Consulting fees$1,50015%
- Speaking & faculty fees$2,75028%
- Food & beverage$5,50256%
- Education$801%
- Entertainment$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch Health US, LLC | 6 | $68,550 |
| Kala Pharmaceuticals, Inc. | 8 | $8,824 |
| Alcon | 29 | $3,581 |
| Vertical Pharmaceuticals, LLC | 1 | $1,500 |
| Amgen(2 entities) | 28 | $753 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $512 |
| Novartis | 40 | $496 |
| Tarsus Pharmaceuticals, Inc. | 14 | $456 |
| Mallinckrodt Hospital Products Inc. | 18 | $441 |
| AbbVie(2 entities) | 13 | $376 |
| Oyster Point Pharma, Inc. | 9 | $251 |
| Thea Pharma Inc. | 10 | $229 |
| Bausch & Lomb Americas Inc. | 11 | $210 |
| Aerie Pharmaceuticals, Inc. | 11 | $185 |
| Sun Pharmaceutical Industries Inc. | 6 | $140 |
| Ivantis, Inc | 1 | $136 |
| ANI Pharmaceuticals, Inc. | 6 | $123 |
| Rxsight Inc | 4 | $91 |
| Lensar, Inc. | 1 | $76 |
| Optos, Inc. | 1 | $45 |
| Beaver-visitec International, Inc. | 1 | $38 |
| Alcon Research LLC | 1 | $35 |
| Shire North American Group Inc | 1 | $29 |
| Akorn, Inc. | 1 | $19 |
| Osmotica Pharmaceutical Corp. | 1 | $19 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis IOL$247
- AcrySof IQ PanOptix UV IOL$144
- Hydrus$136
- Tecnis Simplicity$135
- Clareon$129
- Repatha$116
How this compares
$87,131 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 767 | $851,794 |
| LumiganBimatoprost | 637 | $298,501 |
| VyzultaLatanoprostene Bunod | 712 | $292,906 |
| Cyclosporine | 490 | $248,818 |
| XiidraLifitegrast | 221 | $228,166 |
| CombiganBrimonidine Tartrate/Timolol | 239 | $87,564 |
| Alphagan PBrimonidine Tartrate | 163 | $63,453 |
| XdemvyLotilaner | 34 | $63,129 |
| Brimonidine Tartrate | 372 | $59,714 |
| CequaCyclosporine | 84 | $54,393 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 156 | $49,949 |
| RocklatanNetarsudil Mesylat/Latanoprost | 74 | $37,824 |
| RhopressaNetarsudil Mesylate | 48 | $30,874 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 140 | $30,708 |
| AzoptBrinzolamide | 60 | $30,107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $376 | $1,301,3111,806 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo | $210 | $533,025949 claims |
| AlconSimbrinza, Azopt | $3,581 | $80,057216 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $185 | $68,697122 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $456 | $63,12934 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $140 | $54,39384 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $251 | $12,06019 claims |
| Kala Pharmaceuticals, Inc.Inveltys | $8,824 | $9,74128 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCBepreve, Loteprednol Etabonate | $15 | $7,75626 claims |
| Thea Pharma Inc.Iyuzeh | $229 | $7,56520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Fountain Valley
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.